Neptune to Hold Conference Call
October 11 2011 - 1:31PM
Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT)
(TSX-V:NTB) will be holding a conference call and webcast on
Thursday, October 13, 2011 at 4:30 pm ET.
Topics to be discussed on the call include:
- Second quarter and year-to-date financial results,
- An update on commercial progress,
- Plans for production expansion,
- The recently announced Neptune-SKFC Chinese Joint Venture for
Asian expansion.
The webcast can be accessed in listen‐only mode free of charge,
by clicking the link below:
http://bit.ly/mRGMep
To access the conference call by phone within Canada & the
U.S. the toll‐free number is 1‐877-380-5664. Outside Canada and the
U.S., dial 1‐631-813-4882.
Callers should dial in five to 10 minutes prior to the scheduled
start time and ask to be connected to the "Neptune call."
Management will accept questions by telephone and e‐mail.
Questions can be forwarded in advance or during the presentation to
a.godin@neptunebiotech.com.
An archived recording of the webcast will be available on
Neptune's website (www.neptunebiotech.com) two hours after the
webcast.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain
and forward-looking. The forward-looking statements contained
herein are also subject generally to other risks and uncertainties
that are described from time to time in the Company's reports filed
with the Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dabe@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024